Flecainide
- CAS No.
- 54143-55-4
- Chemical Name:
- Flecainide
- Synonyms
- Flecainide-d4;Flecaine;Flecanide;FLECAINIDE;rac Flecainide;FLECAINTDE BASE;Flecainide USP/EP/BP;(±)-Flecainide solution;(±)-Flecainide solution;N-(Piperidin-2-ylmethyl)
- CBNumber:
- CB0663265
- Molecular Formula:
- C17H20F6N2O3
- Molecular Weight:
- 414.34
- MDL Number:
- MFCD00864713
- MOL File:
- 54143-55-4.mol
- MSDS File:
- SDS
- TDS File:
- TDS
| Melting point | 105-1070C |
|---|---|
| Boiling point | 434.9±45.0 °C(Predicted) |
| Density | 1.286±0.06 g/cm3(Predicted) |
| Flash point | 9℃ |
| storage temp. | Keep in dark place,Inert atmosphere,Room temperature |
| solubility | Chloroform (Slightly), Methanol (Slightly) |
| form | Solid |
| pka | pKa 9.3 (Uncertain) |
| color | White to Off-White |
| BCS Class | 1 or 2 |
| Major Application | clinical testing |
| InChI | 1S/C17H20F6N2O3/c18-16(19,20)9-27-12-4-5-14(28-10-17(21,22)23)13(7-12)15(26)25-8-11-3-1-2-6-24-11/h4-5,7,11,24H,1-3,6,8-10H2,(H,25,26) |
| InChIKey | DJBNUMBKLMJRSA-UHFFFAOYSA-N |
| SMILES | O=C(NCC1CCCCN1)C2=CC(OCC(F)(F)F)=CC=C2OCC(F)(F)F |
| CAS DataBase Reference | 54143-55-4(CAS DataBase Reference) |
| EWG's Food Scores | 1 |
| NCI Dictionary of Cancer Terms | flecainide |
| FDA UNII | K94FTS1806 |
| ATC code | C01BC04 |
| NIST Chemistry Reference | Benzamide, n-(2-piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)-(54143-55-4) |
| UNSPSC Code | 41116107 |
| NACRES | NA.24 |
SAFETY
Risk and Safety Statements
| Symbol(GHS) |    GHS02,GHS06,GHS08 |
|---|---|
| Signal word | Danger |
| Hazard statements | H225-H301+H311+H331-H370 |
| Precautionary statements | P210-P260-P280-P301+P310-P311 |
| target organs | Eyes,Central nervous system |
| Hazard Codes | F,T |
| Risk Statements | 11-23/24/25-39/23/24/25 |
| Safety Statements | 7-16-36/37-45 |
| RIDADR | 3249 |
| WGK Germany | 1 |
| HazardClass | 6.1(b) |
| PackingGroup | III |
| Storage Class | 3 - Flammable liquids |
| Hazard Classifications | Acute Tox. 3 Dermal Acute Tox. 3 Inhalation Acute Tox. 3 Oral Flam. Liq. 2 STOT SE 1 |
| REACH Registrations | Active |
Flecainide price More Price(46)
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| Sigma-Aldrich | F-017 | (±)-Flecainide solution 1.0?mg/mL in methanol, ampule of 1?mL, certified reference material, Cerilliant? | 54143-55-4 | 1mL | $76.9 | 2026-04-30 | Buy |
| Usbiological | F4542 | Flecainide (N-(2-Piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)benzamide) | 54143-55-4 | 100mg | $531 | 2026-06-03 | Buy |
| TRC | TRC-F390000-25MG | Flecainide >95%(HPLC) | 54143-55-4 | 25mg | $145 | 2026-06-03 | Buy |
| TRC | TRC-F390000-10MG | Flecainide >95%(HPLC) | 54143-55-4 | 10mg | $86 | 2026-06-03 | Buy |
| TRC | TRC-F390000-100MG | Flecainide >95%(HPLC) | 54143-55-4 | 100mg | $271 | 2026-06-03 | Buy |
Flecainide Chemical Properties, Uses, Production
Description
From the chemical point, flecainide is an analog of procainamide, to which a 2.2.2-trifluoroethoxyl group was added at C2 and C3 of the benzene ring, and a diaminoethyl side chain is ended in the piperidine ring.
Chemical Properties
White Crystalline Powder
Originator
Tambocor,Kettelhack Riker,W. Germany,1982
Uses
Flecainide, as with other local anesthetics, is used for naturally occurring ventricular arrhythmia.
Uses
Flecainide is an antiarrhythmic (class IC).
Definition
ChEBI: A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 2,5-bis(2,2,2-trifluoroethoxy)benzoic acid with the primary amino group of piperidin-2-ylmethylamine. An antiarrhythmic agent used (in the form of its acetate salt) to prev nt and treat tachyarrhythmia (abnormal fast rhythm of the heart).
Manufacturing Process
Under a nitrogen atmosphere 2-aminomethylpiperidine (0.249 mol, 28.4 g) is treated dropwise over 25 minutes with 2,2,2-trifluoroethyl 2,5-bis(2,2,2- trifluoroethoxy)benzoate (0.0249 mol, 10.0 g). After 3 hours 50 ml of benzene is added to the thick mixture and stirred for about 40 hours at 45°C. The mixture is then concentrated under vacuum with heating to remove the volatile components. The residue solidifies after cooling, is steam distilled for further purification and is separated by filtration and extracted into dichloromethane. The dichloromethane solution is washed with saturated sodium chloride solution, and the organic layer is dried over anhydrous magnesium sulfate. The magnesium sulfate is removed by filtration and 4 ml of 8.4 N hydrogen chloride in isopropanol is added to the dichloromethane solution with stirring.After 2 hours the mixture is cooled to about 0°C and the crude product is collected by filtration, washed with diethyl ether and dried in a vacuum oven. After treatment with decolorizing charcoal and recrystallization from an equivolume mixture of isopropanol and methanol, the product, 2,5-bis(2,2,2- trifluoroethoxy)-N-(2-piperidylmethyl)benzamide hydrochloride has a MP of 228°C to 229°C.
brand name
Tambocor (3M Pharmaceuticals).
Therapeutic Function
Antiarrhythmic
World Health Organization (WHO)
The membrane-stabilizing antiarrhythmic agent flecainide was introduced into medicine in 1982. The decision to delete the indications for patients with asymptomatic and less severe symptomatic ventricular arrhythmias was taken on the basis of the results of a trial (CAST study) that showed a two-fold increase in deaths in post-myocardiac patients taking flecainide compared with the placebo group.
Hazard
Human systemic effects.
Mechanism of action
Flecainide is effective if administered intravenously and orally; its effect is long-lasting. The drug combines the modes of action of class I a and I b drugs with those of class III.
Clinical Use
Flecainide (Tambocor) is a fluorinated aromatic hydrocarbon
examined initially for its local anesthetic
action and subsequently found to have antiarrhythmic
effects. Flecainide inhibits the sodium channel, leading
to conduction slowing in all parts of the heart, but
most notably in the His-Purkinje system and ventricular
myocardium. It has relatively minor effects on repolarization.
Flecainide also inhibits abnormal automaticity.
Flecainide is effective in treating most types of atrial arrhythmias.
It is also used for life-threatening ventricular
arrhythmias. However, flecainide should be used with extreme
caution in any patient with structural heart disease.
Flecainide crosses the placenta, with fetal levels reaching
approximately 70% of maternal levels. In many centers,
it is the second-line drug after digoxin for therapy of fetal
arrhythmias. Because of the high incidence of proarrhythmia,
initiation of therapy or significant increases in
dosing should be performed only on inpatients.
Side effects
Most adverse effects occur within a few days of initial
drug administration. The most frequently reported effects
are dizziness, light-headedness, faintness, unsteadiness,
visual disturbances, blurred vision (e.g., spots before
the eyes, difficulty in focusing), nausea, headache,
and dyspnea.
Worsening of heart failure and prolongation of the PR
and QRS intervals are likely to occur with flecainide, and
an increased risk of proarrhythmia has been reported.
Synthesis
Flecainide, N-(2-piperidylmethyl)-2,5-bis-(2,2,2-trifluoroethoxy)benzamide (18.1.14), is synthesized from 2,5-dihydroxybenzoic acid. Reacting this with trifluoroethylfluoromethylsulfonate gives 2.2.2-trifluoroethoxylation of all three hydroxyl groups, to produce 2,2,2-trifluoroethyl ester of 2,5-bis-(2,2,2-trifluoroethoxy)benzoic acid (18.1.12). Reacting this with 2-aminomethylpiridine gives the corresponding amide (18.1.13), which upon reduction of the pyridine ring with hydrogen gives flecainide (18.1.14).
Drug interactions
In patients whose condition has been stabilized by flecainide, the addition of cimetidine may reduce the rate of flecainide’s hepatic metabolism, increasing the potential for toxicity. Flecainide may increase digoxin concentrations on concurrent administration.
Precautions
Flecainide is contraindicated in patients with preexisting second- or third-degree heart block or with bundle branch block unless a pacemaker is present to maintain ventricular rhythm. It should not be used in patients with cardiogenic shock.
Flecainide Preparation Products And Raw materials
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| J & K SCIENTIFIC LTD. | 18210857532 18210857532 | jkinfo@jkchemical.com | China | 96815 | 76 |
| Adamas Reagent, Ltd. | 400-6009262 15618770481 | yhx@titansci.com | China | 14098 | 59 |
| LGM Pharma | 1-(800)-881-8210 | inquiries@lgmpharma.com | United States | 2110 | 70 |
| Chemsky（shanghai）International Co.,Ltd. | 021-50135380 | shchemsky@sina.com | China | 32273 | 50 |
| Sphinx Scientific Laboratory (Tianjin) Co., Ltd. | 022-66211289-843 13672102692 | contact@sphinxpharm.com | China | 361 | 62 |
| T&W GROUP | 021-61551611 13296011611 | contact@trustwe.com | China | 9884 | 58 |
| S.Z. PhyStandard Bio-Tech. Co., Ltd. | 0755-83725681-603 | China | 4484 | 50 | |
| Beijing HuaMeiHuLiBiological Chemical | 010-56205725 | waley188@sohu.com | China | 12323 | 58 |
| Shanghai Meishui Chemical Technology Co., Ltd | 021-60549325 18616193163 | China | 4518 | 56 | |
| Finetech Industry Limited | 027-87465837 19945049750 | sales@finetechnology-ind.com | China | 9331 | 58 |
View Latest Price from Flecainide manufacturers
| Image | Update time | Product | Price | Min. Order | Purity | Supply Ability | Manufacturer | |
|---|---|---|---|---|---|---|---|---|
 |
2026-05-26 | Flecainide
54143-55-4
|
$198.00 | 99.89% | 10g | TargetMol Chemicals Inc. | ||
 |
2021-08-12 | Flecainide
54143-55-4
|
$10.00-15.00 | 1KG | 99%+ HPLC | Zhuozhou Wenxi import and Export Co., Ltd | ||
 |
2020-02-18 | Flecainide
54143-55-4
|
$7.00 | 1KG | 99% | 100kg | Career Henan Chemical Co |
-
- Flecainide
54143-55-4
- $198.00
- 99.89%
- TargetMol Chemicals Inc.
-
- Flecainide
54143-55-4
- $10.00-15.00
- 99%+ HPLC
- Zhuozhou Wenxi import and Export Co., Ltd
-
- Flecainide
54143-55-4
- $7.00
- 99%
- Career Henan Chemical Co
54143-55-4 (Flecainide) Related Search:
1of4
